BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up – Here’s Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares gapped up prior to trading on Friday . The stock had previously closed at $8.05, but opened at $8.49. BioCryst Pharmaceuticals shares last traded at $7.97, with a volume of 798,615 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Trading Down 3.2 %

The firm has a fifty day simple moving average of $7.60 and a 200 day simple moving average of $7.56. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -12.77 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The company’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.19) EPS. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. Xponance Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 1,505 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after buying an additional 2,644 shares during the last quarter. Creative Planning increased its holdings in BioCryst Pharmaceuticals by 5.9% in the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares in the last quarter. Finally, SkyView Investment Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 3,000 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.